NCT06703658 is a Phase 1 clinical trial of AZD5004(Part A) in Healthy Participants, sponsored by AstraZeneca.

Who is sponsoring NCT06703658?

NCT06703658 is sponsored by AstraZeneca.

What drugs are being tested in NCT06703658?

Interventions in NCT06703658: AZD5004(Part A), Placebo(Part A), AZD5004(Part B), Placebo(Part B).

What condition does NCT06703658 study?

NCT06703658 studies Healthy Participants, Type 2 Diabetes.

Is NCT06703658 still recruiting?

NCT06703658 is currently completed. Last updated 21 March 2025.

Last reviewed 2025-03-21 · How we verify

NCT06703658

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus

Completed Phase 1 Last updated 21 March 2025

What this trial tests

Phase 1 trial testing AZD5004(Part A) in Healthy Participants in 35 participants. Completed in 13 March 2025.

Timeline

2 November 2024

Primary endpoint
13 March 2025

13 March 2025

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	35
Start date	2 November 2024
Primary completion	13 March 2025
Estimated completion	13 March 2025
Sites	1 location across Japan

Drugs / interventions tested

AZD5004(Part A) — full drug profile →
Placebo(Part A)
AZD5004(Part B) — full drug profile →
Placebo(Part B)

Conditions studied

Healthy Participants — all drugs for Healthy Participants →
Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Participants or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase I study will gather important information on the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5004 in both healthy Japanese participants and Japanese participants with T2DM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06703658 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 21 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06703658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing